Search Results
Your search for ,FeW matches 3081 pages
Showing 3001 - 3050Recurrent Ovarian Cancers Respond to Cancer Vaccine After ‘Reprogramming’ With Decitabine
Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with the disease, according to a...
Science Magazine Names Cancer Immunotherapy as Scientific Breakthrough of the Year
While acknowledging that the full potential of cancer immunotherapy remains unclear, the editors of the journal Science said that the approach of using the immune system to attack tumors marks a turning point in the treatment of cancer. The successes of cancer immunotherapy in clinical trials in...
Sustained Complete Responses With Novel Immunotherapy in Lymphoma
Approximately 40% of patients with Hodgkin or non-Hodgkin lymphoma have tumor cells that express the type II latency Epstein-Barr virus (EBV) antigens latent membrane protein 1 (LMP1) and LMP2. T cells specific for these antigens are present in low levels and may be rendered nonreactive by the...
Julie M. Vose, MD, MBA, FASCO, Elected ASCO President for 2015-2016 Term
Julie M. Vose, MD, MBA, FASCO, has been elected President of the American Society of Clinical Oncology (ASCO) for a 1-year term beginning in June 2015. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2014. Additionally, four new members were elected to the...
EUROCARE-5: Trends in Survival for Childhood Cancers
As reported in The Lancet Oncology by Gatta et al, the population-based EUROCARE-5 study has shown improved survival for all childhood cancers combined in Europe between 1999–2001 and 2005–2007 and persistence of regional survival disparities. Study Details The study involved analysis ...
Adjuvant Paclitaxel/Trastuzumab Tolerable, Benefits Women With Stage I HER2-Positive, Node-Negative Breast Cancer
There may be a benefit for treating small HER2-positive tumors and this can be done with little toxicity, according to a multicenter study presented at the 2013 San Antonio Breast Cancer Symposium (Abstract S1-04). Previous studies of chemotherapy plus anti-HER2 treatment for node-negative...
PIK3CA Mutations Predictive of Resistance to Neoadjuvant Therapy in HER2/HR-Positive Breast Cancers
Women with HER2-positive, hormone receptor-positive breast cancer with mutations in the PI3K/AKT pathway may respond poorly to neoadjuvant therapy, German researchers reported at the 2013 San Antonio Breast Cancer Symposium (Abstract S4-06). “We found that very few women with HER2-positive...
Ibrutinib/Rituximab Combination Leads to High Response Rate Among Patients With CLL
Nearly all of the patients with high-risk chronic lymphocytic leukemia (CLL) in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib (Imbruvica) and the antibody rituximab (Rituxan), researchers reported at the 55th American Society of Hematology (ASH) Annual Meeting ...
Choosing Wisely® Initiative Improves Quality and Cost of Care
Five commonly used hematology tests, treatments, and procedures are not always necessary, according to the Choosing Wisely® initiative of the ABIM (American Board of Internal Medicine) Foundation. The American Society of Hematology (ASH) Choosing Wisely list of these five tests was...
Idelalisib Achieves High Response Rates in 'Double-Refractory' Indolent NHL
In patients with indolent B-cell non-Hodgkin lymphoma (NHL) refractory to both rituximab (Rituxan) and an alkylating agent, monotherapy with the selective oral PI3K-delta inhibitor idelalisib produced a high response rate, with responses persisting for 1 year in the average patient, according to...
Novel Agents IPI-145 and ABT-199 Show Encouraging Results in Phase I CLL Studies
Two novel agents—the small-molecule PI3K inhibitor IPI-145 and the Bcl-2 inhibitor ABT-199—show promising activity in chronic lymphocytic leukemia (CLL), according to two phase I studies presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstracts...
Grade 3 Endometrioid Carcinoma With PIK3CA Mutation Linked to Unfavorable Outcome
The presence of PIK3CA missense mutation appears to be associated with shorter disease-specific survival in grade 3 endometrioid but not serous endometrial carcinoma, according to a study in Gynecologic Oncology. Although McIntyre et al found this type of mutation across all histologic types of...
Eight-Gene Profile Predicts Benefit of Adjuvant Trastuzumab in HER2-Negative Disease
The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial suggested that efficacy of adjuvant trastuzumab (Herceptin) extended to patients with HER2-negative breast cancer. In a study reported in the Journal of the National Cancer Institute, Pogue-Geile et al identified and...
Gemtuzumab Ozogamicin Reduces Minimal Residual Disease in Children With High-Risk Acute Myeloid Leukemia
Combining gemtuzumab ozogamicin (Mylotarg) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s Research Hospital. The results appear in the...
Assay-Sensitive Treatment Improves Outcomes in Recurrent Ovarian Cancer
The use of assay-sensitive treatment significantly improved both progression-free survival and overall survival compared with nonsensitive treatment in women with recurrent ovarian cancer, according to the results of a prospective clinical trial reported in Gynecologic Oncology. Thomas Rutherford,...
Personal History of Prostate Cancer Increases Risk of Melanoma
History of severe acne, which is a surrogate for high androgen activity, has been associated with increased risk of prostate cancer and recent data suggest that severe teenage acne is a risk factor for melanoma. In a study reported in the Journal of Clinical Oncology, Wen-Qing Li, PhD, of the...
Imaging Studies May Predict Tumor Response to Antiangiogenic Drugs
Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with antiangiogenic drugs and which will not. In a report published online in PNAS, researchers studied patients with newly diagnosed glioblastoma who were treated with the antiangiogenic agent...
Palliative Care Services and Outcomes Improve Using a Standardized Approach
Standardized criteria for initiating palliative care consultations can substantially improve the care of patients with advanced solid tumors, according to research from Mount Sinai School of Medicine, New York, led by Kerin Adelson, MD, Coordinator for Ambulatory Oncology Quality for the Tisch...
Prolonged Sedentary Behavior Linked to Recurrence of Precancerous Colorectal Tumors in Men
Men who spend the most time engaged in sedentary behaviors are at greatest risk for recurrence of colorectal adenomas, benign tumors that are known precursors of colorectal cancers, according to results presented at the 12th Annual AACR International Conference on Frontiers in Cancer Prevention...
Study Clarifies Value—and Limitations—of Patient Assistance Programs for Women With Breast Cancer
Patient assistance programs can help patients with breast cancer meet a variety of needs that might otherwise interfere with getting recommended adjuvant therapies such as radiation, chemotherapy, and hormonal treatments, according to a study published recently in the online edition of...
Combining Metformin With Chemotherapy and Radiation May Improve Outcomes in Lung Cancer Patients
Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggested new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania. The findings will be presented by...
New Nanopharmaceutical May Be Able to Overcome Resistance to Antiangiogenic Treatment
The nanopharmaceutical CRLX101, a novel inhibitor of topoisomerase-1 and hypoxia-inducible factor (HIF)-1 alpha, may be capable of overcoming resistance of tumors to antiangiogenic agents, according to preclinical and early clinical studies that have evaluated CRLX101 in combination with...
Long-Term Obesity Is Linked With Poorer Pancreatic Cancer Survival
Although multiple studies have shown that high body mass index (BMI) is associated with an increased risk of developing pancreatic cancer, few studies have evaluated the impact of BMI on survival and none have used prospectively collected data on BMI. Now a large prospective study by Brian M....
Intervention Program Improves Sun Protection Practices Among Children of Melanoma Survivors
Children of melanoma survivors were more likely to wear hats and reapply sunscreen after receiving a multimedia informational program designed specifically for them. These new findings were included in research published in Cancer Epidemiology, Biomarkers & Prevention. A team of researchers...
Ramucirumab Prolongs Survival in Advanced Gastric Cancer
An investigational targeted drug that reduces blood flow to tumors prolonged the survival of patients with advanced stomach cancer after standard treatments failed, according to results of large multicenter clinical trial reported by Charles S. Fuchs, MD, MPH, of Dana-Farber Cancer Institute, and...
ECC 2013: Molecular Sequencing Identifies Drug Targets for Cancers of Unknown Primary Origin
Cancers of unknown primary origin pose a treatment dilemma for oncologists and a great deal of anxiety for patients and their families. A study reported at the European Cancer Congress 2013 in Amsterdam (Abstract LBA39) shows that molecular profiling can identify targetable mutations in up to 80%...
ECC 2013: Multiple Studies Validate Long-Term Survival Benefit of Ipilimumab in Melanoma
There is no longer any doubt that for the treatment of metastatic or locally advanced melanoma, ipilimumab (Yervoy) conveys long-term survival benefits, according to studies presented at the European Cancer Congress 2013. In the largest survival analysis of the CTLA-4 monoclonal antibody to date...
Repurposed Antidepressants May Have Potential to Treat Small Cell Lung Cancer
A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small cell lung cancer, according to a study published in Cancer Discovery. Based on data generated using bioinformatics, two drugs approved by the U.S. Food and ...
For Pregnant Women With Lymphoma, Standard Combination Chemotherapy Given After First Trimester Associated With Few Complications
Lymphoma is the fourth most frequent cancer to occur during pregnancy. In a multicenter retrospective analysis reported in Journal of Clinical Oncology, Andrew M. Evens, DO, MSc, of Tufts University Medical School, and colleagues examined treatment, complications, and outcomes for Hodgkin lymphoma...
ASTRO: Proton Therapy Yields Encouraging Outcomes for Pediatric Brain Tumor Patients
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented on Sunday, September 22, at the American Society for Radiation Oncology’s 55th Annual Meeting...
New Report Examines Trends in End-of-Life Care for Patients With Advanced Cancer
Although fewer Medicare patients with cancer died in the hospital in 2010 than in the years 2003–2007, aggressive treatment continues at the end of life, according to a new report from the Dartmouth Atlas Project. The findings also show that a significant number of patients were likely to...
Quality of Life Improves Over Time and Is Similar in Long-Term Breast Cancer Survivors and Women With No History of Breast Cancer
In a study reported in Journal of Clinical Oncology, Pamela J. Goodwin, MD, and Tina Hsu of University of Toronto and colleagues assessed changes in quality of life from time of breast cancer diagnosis to long-term survivorship and compared quality of life in long-term survivors to that of...
NCI Study Links Hodgkin Lymphoma Treatment to Risk of Stomach Cancer
Hodgkin lymphoma survivors who received subdiaphragmatic radiotherapy and chemotherapy regimens containing high doses of the alkylating agent procarbazine (Matulane) were at an increased risk of developing stomach cancer, according to a large study by scientists at the National Cancer Institute...
New Screening Strategy May Detect Ovarian Cancer at Early Stages
A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal. The strategy was described in a study published early online this week in Cancer. A clinical trial is ongoing to verify the findings. Karen Lu, MD, of The University of...
Many Patients With Head and Neck Cancer Report Being Depressed, But Few Use Mental Health Services
Despite a relatively high rate of depression among patients with head and neck cancer following radiation therapy, mental health services were severely underutilized in this group, concluded researchers who analyzed questionnaire results from 211 patients. The patients had been previously treated...
Best of ASCO 2013: VeriStrat Assay May Help Select NSCLC Patients for Second-Line Therapy
VeriStrat, a serum-based protein assay, can help select which patients with non–small cell lung cancer (NSCLC) who are not known to have epidermal growth factor receptor (EGFR) mutations might benefit from an EGFR-targeted agent, according to a study described at the 2013 Best of ASCO Los...
Best of ASCO 2013: Promises and Challenges of Applying Molecular Profiling to Clinical Practice
A “new kind of pathology,” in which anatomy and histology are supplemented by molecular etiology, has been emerging over the past decade and promises better response rates among cancer patients as genomic alterations in cancer continue to be identified and treated with targeted...
Researchers Identify Gene Variations in Lung Cancer Patients That May Help Predict an Individual’s Treatment Response
Researchers at the Moffitt Cancer Center have identified four inherited genetic variants in patients with non–small cell lung cancer that can help predict survival and treatment response. Their findings, published in Carcinogenesis, could help lead to more personalized treatment options and...
Vaccine Stirs Immune Activity Against Advanced Chronic Lymphocytic Leukemia
Patients with advanced chronic lymphocytic leukemia (CLL) often receive allogeneic transplants that effectively “reboot” their own immune defenses, which then attack and potentially cure the hard-to-treat disease. However, there is a high rate of relapse in these patients, and the...
Long-Term Calcium-Channel Blocker Use for Hypertension Associated With Higher Breast Cancer Risk
Long-term use of a calcium-channel blocker to treat hypertension is associated with higher breast cancer risk, according to a report published by JAMA Internal Medicine. The study assessed the relationships between the major classes of hypertensive agents and risk of the two most common histologic...
Experts Discuss Challenges in Counseling Patients About Contralateral Prophylactic Mastectomy
Many factors play into why women diagnosed with breast cancer often choose overly aggressive treatment even when there is little evidence to show clinical benefit: the shock and fear of suddenly being confronted with a major health threat, the impression of having to make treatment decisions...
Benefit Seen with Both Autologous and Allogeneic Hematopoietic Cell Transplantation in T-cell Non-Hodgkin Lymphoma
In a report in Journal of Clinical Oncology, Sonali M. Smith, MD, of University of Chicago Hospitals, and colleagues analyzed outcomes in a large cohort of autologous or allogeneic hematopoietic cell transplantation recipients with the most common T-cell non-Hodgkin lymphoma histologies. Their ...
Higher Incidence of Non-Hodgkin Lymphoma Found in Regions with Close Proximity to Benzene Release Sites
The incidence of a non-Hodgkin lymphoma (NHL) is significantly higher in regions near facilities that release the chemical benzene into the environment, according to a new study published early online in Cancer. This and other studies like it will be critical to identifying and enacting public...
National Lung Screening Trial Analysis Supports Risk-based Targeting of Smokers for Low-dose CT Screening
The National Lung Screening Trial (NLST) showed that screening with low-dose computed tomography (CT) resulted in a 20% reduction in lung cancer mortality compared with chest radiography in participants aged 55 to 74 years with a minimum of 30 pack-years of smoking and no more than 15 years since...
Progesterone and Estrogen Receptor Expression Are Prognostic Markers for Endometrioid and High-grade Serous Ovarian Cancer
Few markers of ovarian cancer prognosis have been established, perhaps because potential subtype associations are missed in studies including patients with all histopathologic subtypes. In a study reported in Lancet Oncology, Weiva Sieh, PhD, of Stanford University and colleagues assessed the...
HPV Vaccine Reduces Prevalence of Oral HPV Infections in Costa Rican Study
A new study by the International Agency for Research on Cancer (IARC), in partnership with Costa Rican investigators and the National Cancer Institute (NCI), shows for the first time that the vaccine against human papillomavirus (HPV) types 16 and 18, which is used to prevent cervical cancer, also...
Accelerated Partial-breast Irradiation Using 3D Conformal Radiation Therapy Causes More Adverse Events Compared with Whole-breast Irradiation
The RAPID trial compared accelerated partial-breast irradiation using three-dimensional (3D) conformal external-beam radiation therapy vs whole-breast irradiation in women with invasive or in situ breast cancer ≤ 3 cm. As reported by Ivo A. Olivotto, MD, FRCPC, of the British Columbia Cancer...
Bevacizumab/Pemetrexed Maintenance Increases Progression-free Survival vs Bevacizumab Alone in Advanced Nonsquamous NSCLC
Maintenance therapy is associated with improved survival in non–small cell lung cancer (NSCLC), but few studies have compared active agents in this setting. In a phase III trial (AVAPERL trial) reported in Journal of Clinical Oncology by Fabrice Barlesi, MD, PhD, of Aix Marseille...
Significant Improvement in Overall Survival Seen with Pemetrexed Maintenance after Pemetrexed/Cisplatin Induction in Patients with Advanced NSCLC
In the phase III PARAMOUNT trial, pemetrexed (Alimta) continuation maintenance therapy significantly reduced the risk of disease progression by 38% compared with placebo after pemetrexed/cisplatin induction in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Final...
Targeting Errant Immune System Enzyme Kills Myelodysplastic Cells
Scientists have successfully targeted a malfunctioning immune system enzyme to kill diseased cells from patients with myelodysplastic syndrome (MDS), a precursor to acute myeloid leukemia (AML). Reporting their results in Cancer Cell, researchers say their successful laboratory tests in human MDS...
